胰岛素是肥胖（局部肥胖或全身肥胖）唯一的原因，因为它是唯一能合成脂肪并阻止脂肪分解（脂解）的激素。
原始表述
الانسولين هو السبب الوحيد الاوحد للسمنه موضعيه كانت او الابديمه متحجره متحشره الانسولين يا باشا الهرمون الوحيد الذي يكون الدهون
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
胰岛素是肥胖（局部肥胖或全身肥胖）唯一的原因，因为它是唯一能合成脂肪并阻止脂肪分解（脂解）的激素。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- المفاهيم المضللة عن الإنسولين ومغالطات شائعه حول الإنسولين #ضياء_العوضي (打开来源)
- 发布日期
- 2026年4月17日
- 时间戳
- 0:05:21 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
- 所声称的机制
Insulin inhibits lipolysis and promotes fat storage; therefore insulin alone causes obesity.
- 所声称的健康影响
Obesity; also: insulin treatment makes people fat.
- 涉及人群
General population; people with diabetes treated with insulin
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/insulin-injections/
- 归属的不确定性
- The archive's 'د. ضياء يقول' box gives no video reference; wording is the archive's paraphrase.
لك السمنه هي اللي ورا السكر السمنه هي اللي ورا السكر طب اذا كان يروح امك الانسولين هو الهرمون الوحيد المسبب للسمنه ها يعني شوف المفاجاه بقى الصادمه الصادمه اللي هي بتقول
Insulin is the only hormone that causes obesity; obesity is not what causes diabetes.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا تصليح مفاهيم (打开来源)
- 发布日期
- 2026年3月31日
- 时间戳
- 1:05:27 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Insulin is the sole cause of all obesity and the only hormone that forms fat and blocks lipolysis.
2. 哪些内容可证实是正确的？
Insulin is the main anabolic hormone of fat tissue: it suppresses lipolysis and promotes fat storage. Starting or intensifying insulin therapy in type 2 diabetes causes weight gain: in UKPDS 33 patients assigned insulin gained 4.0 kg vs 1.7-2.6 kg with sulfonylureas (A-INS-16); weight gain rises with insulin dose and intensity (A-INS-17, A-INS-18).
3. 哪些内容是错误或夸大的？
'Only cause' is not supported. Obesity is multifactorial (energy intake, food environment, ultra-processed foods, genetics, sleep, medications, physical activity). In a metabolic-ward crossover study, cutting dietary fat (which barely changes insulin) produced more body-fat loss (89 g/day) than cutting carbohydrate (53 g/day) even though carbohydrate restriction lowered insulin (I-INS-09). Other hormones (cortisol excess, hypothyroidism, sex hormones, leptin deficiency) and drugs also influence fat mass. People with type 1 diabetes and absent insulin lose weight and fat rapidly, which shows insulin is needed to store fat but does not show it is the only cause of obesity. In a related passage (3j32fjfYRbU) he argues against the view that obesity is behind type 2 diabetes. This is contradicted by randomised evidence: in DiRECT, a weight-management programme led to diabetes remission in 46% vs 4% of controls, and remission rose with the amount of weight lost (86% with >=15 kg) (I-FAST-12).
4. 哪些内容仍不明确？
The relative weight of insulin-driven mechanisms versus energy intake in long-term human obesity (the 'carbohydrate-insulin model' versus the 'energy balance model') is still debated in the literature; this debate does not support the 'only cause' wording.
5. 哪些研究支持该说法？
A-INS-16, A-INS-17, A-INS-18 (weight gain with insulin therapy, dose-related); A-INS-19 (metformin reduces insulin dose and weight gain); I-INS-120 (mice with prevented hyperinsulinaemia protected from diet-induced obesity); partly I-INS-118 (low-carbohydrate diet raised energy expenditure during weight maintenance).
6. 哪些研究与该说法相矛盾？
I-INS-09 (fat restriction > carbohydrate restriction for fat loss at equal calories); I-INS-117 (meta-analysis of 32 controlled feeding studies); I-INS-119 (higher-insulin low-fat diet reduced intake by about 690 kcal/day); I-SYS-05 (DIETFITS: no effect modification by insulin secretion).
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
体重增加是2型糖尿病胰岛素治疗的一种真实存在的副作用，这是使用最低有效剂量的理由，也是在适当情况下优先选择不影响体重或能减轻体重的药物的理由。但这不是把胰岛素视为所有肥胖原因的理由，也不是停用医生开具的胰岛素的理由。
评估详情
- 证据确定性的依据
Physiology (insulin is anti-lipolytic and lipogenic) and weight gain under insulin therapy are well established in RCTs and meta-analyses (high certainty). The claim that insulin is the only cause of obesity is contradicted by controlled feeding studies showing that body-fat loss depends on energy balance more than on insulin lowering (moderate certainty; few, short metabolic-ward studies).
- 来源质量
Own words in a machine transcript (verbatim); archive paraphrase consistent.
- 地区可推广性
Physiology is universal.
- 个体例外情况
Some people gain more weight on insulin than others; weight gain depends on dose and regimen (A-INS-17).
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Is insulin the single cause of obesity, and the only hormone that builds fat and blocks lipolysis?
研究问题详解 (PECO)
- 人群
- Adults with and without diabetes
- 干预或暴露
- Insulin (endogenous hyperinsulinaemia; dietary carbohydrate; insulin therapy)
- 对照
- Lower insulin exposure at equal energy intake
- 地域范围
- universal biology
- 结局指标
- Body fat / weight
- Energy expenditure and intake
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS 33: weight gain with insulin therapy.
- 实际结果
- +4.0 kg with insulin vs 1.7-2.6 kg with sulfonylureas.
- 方法学质量
- high (RCT)
- 相关性
- direct for 'insulin therapy causes weight gain'
- 局限
- Does not address other causes of obesity.
Low-carbohydrate diets and calories burned after weight loss
Low-carbohydrate diet increased energy expenditure during weight maintenance, most in high insulin secretors.
- 实际结果
- +209 kcal/d (91-326) low vs high carbohydrate.
- 方法学质量
- moderate (RCT; analyses debated)
- 相关性
- indirect
- 局限
- Not replicated; does not show exclusivity.
Mice that cannot overproduce insulin do not get fat on a high-fat diet
Mice with genetically prevented hyperinsulinaemia were protected from diet-induced obesity.
- 实际结果
- Complete protection from diet-induced obesity.
- 方法学质量
- moderate (animal genetics)
- 相关性
- very indirect (mice)
- 局限
- Animal model.
哪些证据不支持该说法？
Calories, carbohydrates and body fat in controlled feeding studies
Hall KD, Guo J. Gastroenterology 2017 · PMID 28193517 · DOI 10.1053/j.gastro.2017.01.052 Meta分析已核查摘要新增Meta-analysis of 32 controlled feeding studies.
- 实际结果
- Lower-fat diets: +26 kcal/d expenditure and +16 g/d fat loss vs lower-carbohydrate at equal calories.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Short studies.
Low-fat plant diet versus ketogenic animal diet: how much people eat
Inpatient crossover: low-fat (higher insulin) vs ketogenic diet.
- 实际结果
- 689 kcal/d less intake on low-fat diet.
- 方法学质量
- moderate (RCT, small)
- 相关性
- direct
- 局限
- 2 weeks per diet.
Low-fat and low-carb diets led to similar weight loss
DIETFITS: 12-month weight loss did not differ by diet or by insulin secretion.
- 实际结果
- -5.3 vs -6.0 kg; no insulin-secretion interaction.
- 方法学质量
- high (RCT, n=609)
- 相关性
- direct test of insulin-secretion effect modification
- 局限
- Free-living adherence.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Insulin promotes fat storage and insulin therapy causes weight gain, but obesity is multifactorial; insulin is not the only cause.
为什么有些研究权重更大
Human RCTs and controlled feeding outweigh animal data; supporting human data show a role, not exclusivity.
因果关系是否已确立？ 很可能 Insulin's lipogenic, anti-lipolytic action is established; a contributory causal role in obesity is plausible; 'only cause' is not supported.
仍存在的不确定性
Relative weight of the carbohydrate-insulin model vs energy-balance model in long-term human obesity.
合理的结论
Mostly false as stated.
为什么研究结果看起来互相矛盾？
Ebbeling 2018 (supporting) and Hall 2017/2021 (contradicting) differ in phase (weight maintenance vs controlled feeding/ad libitum intake), duration and analytic choices; neither supports 'only cause'.
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- Applies to Egyptian and European diets alike.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Magnitude of effect – Differences of 26 kcal/d and 16 g/d fat are small; direction opposes the insulin-only hypothesis 无法根据已发表数据重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Body fat change when insulin is lowered at equal energy intake
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (short-term feeding studies)
- inconsistency (Ebbeling 2018)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 8. Obesity and Weight Management: Standards of Care in Diabetes-2026 (2026) · 原始文献
Sustained loss of >10% body weight may lead to remission of type 2 diabetes (A); weight loss reduces the need for glucose-lowering drugs, particularly insulin.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"insulin") AND (TITLE:"obesity" OR TITLE:"adiposity") AND (TITLE:"cause" OR TITLE:"causal" OR TITLE:"hyperinsulinemia drives") | 支持性证据 | 29 | |
| Europe PMC | 2026年10月26日 | "carbohydrate-insulin model" AND (TITLE:"obesity") AND PUB_YEAR:[2018 TO 2026] | 支持性证据 | 72 | |
| PubMed | 2026年10月26日 | Ebbeling CB[au] AND "energy expenditure" AND BMJ[ta] | 支持性证据 | 1 | |
| PubMed | 2026年10月26日 | "insulin therapy" AND "weight gain" AND "type 2 diabetes" AND meta-analysis[pt] | 支持性证据 | 19 | |
| PubMed | 2026年10月26日 | "carbohydrate-insulin model" AND (randomized OR meta-analysis) AND (energy expenditure OR body fat) | 双向 | 7 | |
| PubMed | 2026年10月26日 | Hall KD[au] AND Guo J[au] AND "Obesity Energetics" | 反对性证据 | 1 | |
| PubMed | 2026年10月26日 | Hall KD[au] AND (plant-based OR "animal-based") AND ketogenic AND Nat Med[ta] | 反对性证据 | 1 |
核查深度如何？
11 项相关研究：1 项核查了全文（其中 1 项进行了结构化偏倚风险评估），10 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本错误 (中)
New supporting (Ebbeling 2018, Mehran 2012) and contradicting (Hall 2017, Hall 2021, DIETFITS reused) evidence keeps the balance: insulin has a role, but 'only cause' is not supported.
新来源: I-INS-117 I-INS-118 I-INS-119 I-INS-120
通俗解释
胰岛素是一种储存激素，它确实帮助身体储存脂肪。2型糖尿病患者开始使用胰岛素后，体重往往会增加几公斤。但肥胖有很多原因，研究表明，即使胰岛素几乎没有变化，少摄入热量也能减少体脂。所以，胰岛素是众多因素之一，而不是唯一原因。
与该说法相关的研究
支持该说法的研究 (5)
-
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS Group. Lancet 1998 · PMID 9742976随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intensive control with sulfonylurea or insulin vs diet on complications
- 研究是如何开展的？
Multicentre RCT (UKPDS 33)
- 研究了多少人、动物或样本？
3,867; Newly diagnosed type 2 diabetes, median age 54
- 实际发现了什么？
Microvascular -25%; more hypoglycaemia and weight gain with insulin.
- 观察到的效应有多大？
RR reduction 25% microvascular
- 研究结果对日常生活意味着什么？
Insulin helps prevent complications but has side effects.
- 该研究有哪些局限？
Open-label; Older drug regimens
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
That insulin is harmful overall.
-
Weight gain with insulin
Pontiroli AE et al.. Diabetes Obes Metab 2011 · PMID 21645195 · DOI 10.1111/j.1463-1326.2011.01433.xMeta分析被 Tayebat 档案网站引用已核查摘要The more intensive the insulin treatment, the more weight people gain in the first year.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Weight increase in first year of insulin treatment and predictors
- 研究是如何开展的？
Systematic review and meta-analysis of 46 RCTs
- 研究了多少人、动物或样本？
46 RCTs; Type 2 diabetes starting/intensifying insulin
- 实际发现了什么？
Weight gain related to intensity and regimen.
- 观察到的效应有多大？
not reported in abstract
- 研究结果对日常生活意味着什么？
Weight gain is a real insulin side effect.
- 该研究有哪些局限？
Effect sizes not in abstract; Heterogeneous trials
- 它对 Elawady 的具体说法说明了什么？
Supports weight-gain kernel of C-INS-01.
- 研究结果是否适用于德国和欧洲？
International.
- 从该研究中明确不能得出什么结论？
That insulin causes obesity in general.
-
Intensive insulin in 14 patients
Henry RR et al.. Diabetes Care 1993 · PMID 8422777 · DOI 10.2337/diacare.16.1.21病例系列 / 病例报告被 Tayebat 档案网站引用已核查摘要Blood sugar normalised but patients gained almost 9 kg in six months.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 极低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Metabolic effects of intensive conventional insulin in type 2 diabetes
- 研究是如何开展的？
Uncontrolled 6-month clinical study
- 研究了多少人、动物或样本？
14; Type 2 diabetes outpatients
- 实际发现了什么？
Glucose improved; +8.7 kg.
- 观察到的效应有多大？
+8.7 kg
- 研究结果对日常生活意味着什么？
Insulin works but can cause substantial weight gain.
- 该研究有哪些局限？
n=14; No control; 1993 regimen
- 它对 Elawady 的具体说法说明了什么？
Kernel of C-INS-01.
- 研究结果是否适用于德国和欧洲？
Old US regimen.
- 从该研究中明确不能得出什么结论？
General conclusions.
-
Adding metformin to insulin
Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133随机对照试验被 Tayebat 档案网站引用已核查摘要Metformin improved sugar control and reduced insulin need and weight gain.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Metformin added to intensive insulin in type 2 diabetes
- 研究是如何开展的？
Double-blind placebo-controlled RCT
- 研究了多少人、动物或样本？
390; Insulin-treated type 2 diabetes
- 实际发现了什么？
Better control, less insulin, less weight gain.
- 观察到的效应有多大？
GHb -0.7%
- 研究结果对日常生活意味着什么？
Combination lowers insulin needs.
- 该研究有哪些局限？
Short duration; Dropouts higher with metformin
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Dutch data.
- 从该研究中明确不能得出什么结论？
That insulin can be stopped.
-
Mice that cannot overproduce insulin do not get fat on a high-fat diet
Mehran AE et al.. Cell Metab 2012 · PMID 23217255 · DOI 10.1016/j.cmet.2012.10.019动物研究独立交叉核查已核查摘要★ 关键研究Mice genetically prevented from producing excess insulin were protected from diet-induced obesity.
Animal evidence that high insulin drives diet-induced obesity (role, not exclusivity).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether high insulin causes obesity in mice.
- 研究是如何开展的？
Genetic mouse experiment.
- 研究了多少人、动物或样本？
Mice.
- 实际发现了什么？
Less insulin = no diet-induced obesity.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Insulin can promote fat gain, at least in mice.
- 该研究有哪些局限？
Animal study.
- 它对 Elawady 的具体说法说明了什么？
Partly supports a role of insulin; not 'only cause' in humans.
- 研究结果是否适用于德国和欧洲？
Not directly transferable.
- 从该研究中明确不能得出什么结论？
Cannot show insulin is the only cause of human obesity.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (5)
-
Low-fat vs low-carb in a metabolic ward
Hall KD et al.. Cell Metab 2015 · PMID 26278052 · DOI 10.1016/j.cmet.2015.07.021随机对照试验独立交叉核查全文，含结构化偏倚风险评估Cutting fat led to more fat loss than cutting carbs, even though cutting carbs lowered insulin more.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does carbohydrate restriction (lower insulin) cause more fat loss than fat restriction at equal calories?
- 研究是如何开展的？
Randomised crossover metabolic-ward study
- 研究了多少人、动物或样本？
19 adults with obesity randomised (17 completed both diets)
- 实际发现了什么？
Fat loss 89 g/day on reduced-fat vs 53 g/day on reduced-carbohydrate (463 g vs 245 g over 6 days), although only the low-carb diet lowered insulin (by 22%).
- 观察到的效应有多大？
+36 g/day with fat restriction
- 研究结果对日常生活意味着什么？
Calories matter; insulin is not the only driver.
- 该研究有哪些局限？
Only 6 days per diet; small sample; fat loss was a secondary outcome; long-term predictions come from a computer model; moderate (not very-low) carbohydrate restriction.
- 它对 Elawady 的具体说法说明了什么？
Contradicts C-INS-01 ('insulin the only cause of fat').
- 研究结果是否适用于德国和欧洲？
Physiology transferable.
- 从该研究中明确不能得出什么结论？
Long-term weight outcomes.
-
DiRECT: weight loss to put type 2 diabetes into remission
Lean ME et al.. Lancet 2018 · PMID 29221645 · DOI 10.1016/S0140-6736(17)33102-1随机对照试验独立交叉核查已核查摘要★ 关键研究46% of people in the programme were free of diabetes and medication after one year.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Can intensive weight management in primary care achieve T2D remission?
- 研究是如何开展的？
Open-label cluster-randomised trial (DiRECT)
- 研究了多少人、动物或样本？
306 (149 per group ITT); 49 practices; Age 20-65, T2D <6 years, BMI 27-45, not on insulin
- 实际发现了什么？
Remission 46% vs 4%.
- 观察到的效应有多大？
OR 19.7
- 研究结果对日常生活意味着什么？
Losing 10-15 kg can reverse early type 2 diabetes.
- 该研究有哪些局限？
Open-label; Selected population; Formula diet
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
Effect of the Tayebat diet; effect in type 1 or insulin-treated diabetes.
-
Low-fat and low-carb diets led to similar weight loss
Gardner CD et al.. JAMA 2018 · PMID 29466592 · DOI 10.1001/jama.2018.0245随机对照试验独立交叉核查已核查摘要After a year, weight loss was 5.3 kg vs 6.0 kg - no real difference.
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare diets.
- 研究是如何开展的？
RCT.
- 研究了多少人、动物或样本？
609.
- 实际发现了什么？
No difference.
- 观察到的效应有多大？
0.7 kg.
- 研究结果对日常生活意味着什么？
Total diet quality and quantity matter more than fat share.
- 该研究有哪些局限？
Adherence.
- 它对 Elawady 的具体说法说明了什么？
Supports 'fat is not the origin'.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Long-term weight maintenance.
-
Calories, carbohydrates and body fat in controlled feeding studies
Hall KD, Guo J. Gastroenterology 2017 · PMID 28193517 · DOI 10.1053/j.gastro.2017.01.052Meta分析独立交叉核查已核查摘要★ 关键研究When calories were fixed, cutting fat led to slightly more fat loss than cutting carbohydrate, even though carbohydrate cuts lower insulin.
At equal calories, lower-fat diets gave slightly more fat loss despite higher insulin.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether lowering insulin via low-carbohydrate diets increases fat loss.
- 研究是如何开展的？
Meta-analysis of 32 controlled feeding studies.
- 研究了多少人、动物或样本？
Adults in metabolic studies.
- 实际发现了什么？
Lower-fat diets: +26 kcal/d expenditure, +16 g/d fat loss.
- 观察到的效应有多大？
Small effects.
- 研究结果对日常生活意味着什么？
Insulin is one factor, but calories matter.
- 该研究有哪些局限？
Short studies.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'insulin is the only cause of obesity'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot settle long-term diet debates.
-
Low-fat plant diet versus ketogenic animal diet: how much people eat
Hall KD et al.. Nat Med 2021 · PMID 33479499 · DOI 10.1038/s41591-020-01209-1随机对照试验独立交叉核查已核查摘要★ 关键研究On a high-carbohydrate low-fat diet people ate about 690 fewer calories per day than on a ketogenic diet.
Higher-insulin low-fat diet reduced intake by about 690 kcal/day.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test the carbohydrate-insulin model on food intake.
- 研究是如何开展的？
Inpatient crossover trial.
- 研究了多少人、动物或样本？
20 adults.
- 实际发现了什么？
Low-fat diet: 689 kcal/d less intake.
- 观察到的效应有多大？
-689 kcal/d.
- 研究结果对日常生活意味着什么？
Insulin is not the only factor in weight gain.
- 该研究有哪些局限？
Short and small.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'insulin is the only cause of obesity'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot predict long-term weight change.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Low-carbohydrate diets and calories burned after weight loss
Ebbeling CB et al.. BMJ 2018 · PMID 30429127 · DOI 10.1136/bmj.k4583随机对照试验独立交叉核查已核查摘要★ 关键研究People on a low-carbohydrate diet burned about 200 more calories per day than on a high-carbohydrate diet while keeping weight off.
Supports a role of carbohydrate/insulin in energy expenditure; does not support 'only cause'.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test diet carbohydrate and energy expenditure.
- 研究是如何开展的？
Randomised trial over 20 weeks.
- 研究了多少人、动物或样本？
164 adults after weight loss.
- 实际发现了什么？
Low-carb: +209 kcal/d.
- 观察到的效应有多大？
52 kcal/d per 10% less carbohydrate.
- 研究结果对日常生活意味着什么？
Insulin may play some role in weight regulation.
- 该研究有哪些局限？
Results debated; correction published.
- 它对 Elawady 的具体说法说明了什么？
Partly supports a role of insulin, not 'only cause'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot show insulin is the only cause.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 胰岛素会促进脂肪储存，胰岛素治疗也会导致体重增加，但它并不是肥胖的唯一原因。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.. Pontiroli AE et al.. Diabetes Obes Metab 2011 · PMID 21645195 · DOI 10.1111/j.1463-1326.2011.01433.x
- Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.. Henry RR et al.. Diabetes Care 1993 · PMID 8422777 · DOI 10.2337/diacare.16.1.21
- Combination of insulin and metformin in the treatment of type 2 diabetes.. Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133
- Hyperinsulinemia drives diet-induced obesity independently of brain insulin production.. Mehran AE et al.. Cell Metab 2012 · PMID 23217255 · DOI 10.1016/j.cmet.2012.10.019
- Calorie for Calorie, Dietary Fat Restriction Results in More Body Fat Loss than Carbohydrate Restriction in People with Obesity.. Hall KD et al.. Cell Metab 2015 · PMID 26278052 · DOI 10.1016/j.cmet.2015.07.021
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.. Lean ME et al.. Lancet 2018 · PMID 29221645 · DOI 10.1016/S0140-6736(17)33102-1
- Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.. Gardner CD et al.. JAMA 2018 · PMID 29466592 · DOI 10.1001/jama.2018.0245
- Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition.. Hall KD, Guo J. Gastroenterology 2017 · PMID 28193517 · DOI 10.1053/j.gastro.2017.01.052
- Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake.. Hall KD et al.. Nat Med 2021 · PMID 33479499 · DOI 10.1038/s41591-020-01209-1
- Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial.. Ebbeling CB et al.. BMJ 2018 · PMID 30429127 · DOI 10.1136/bmj.k4583